Biofrontera Launches FDA-Approved RhodoLED® XL Lamp

Biofrontera Inc., a biopharmaceutical company specializing in dermatologic products, has introduced its FDA-approved RhodoLED XL, a red light emitting LED lamp designed for photodynamic therapy (PDT). This advanced device signifies a major step forward in PDT treatments, thanks to its cutting-edge engineering, durable yet sleek construction, and an easy-to-use interface. The RhodoLED XL is particularly user-friendly, offering flexibility in patient positioning to enhance the treatment process.

The RhodoLED XL is designed to work in combination with Biofrontera's FDA-approved PDT drug, Ameluz, which contains aminolevulinic acid hydrochloride. This combination is utilized to treat actinic keratoses of mild-to-moderate severity on the face and scalp. The introduction of the RhodoLED XL allows for the illumination of a larger treatment area in a single PDT session, making it a valuable addition to dermatological practices.

Dr. Hermann Luebbert, CEO of Biofrontera Inc., expressed his enthusiasm about the launch, stating, "We are delighted to introduce the RhodoLED XL lamp to the dermatology community in the US. This new device underscores our commitment to innovation and excellence, providing dermatologists with a powerful tool to deliver superior patient care. The XL lamp's advanced features and user-friendly design will undoubtedly set a new standard in photodynamic therapy."

Compared to Biofrontera's existing lamp, the RhodoLED XL features a larger illumination area with five panels instead of one. It also includes positioning sensors to ensure optimal energy delivery from the LED array, enhancing the effectiveness of treatments. Dr. Luebbert added, "I’m pleased to say we have already shipped three of these new devices to customers in our first week of launch and the response from dermatology organizations across the US has been very encouraging."

Cleaver Dermatology, a well-known practice with locations in Missouri and Georgia, was the first to integrate the RhodoLED XL lamp into their operations. Dr. David Cleaver of Cleaver Dermatology expressed his satisfaction, saying, "We are honored to be the first to integrate the XL lamp into our practice. The advanced features and versatility of this device represent a considerable upgrade on what has been available until now and will allow us to provide our patients with the highest standard of care. In addition, we have been very pleased with the level of customer service that the team at Biofrontera has delivered."

Biofrontera launched the commercial distribution of the RhodoLED XL on June 10, 2024, and shipped the first three machines within one week of the launch. This swift deployment highlights the company's efficiency and the high demand for such innovative devices in the field of dermatology.

Biofrontera Inc. is a U.S.-based biopharmaceutical company focused on commercializing pharmaceutical products for dermatological conditions, especially those treated with photodynamic therapy and topical antibiotics. Their products are primarily used to treat actinic keratoses, pre-cancerous skin lesions, and impetigo, a bacterial skin infection. The launch of the RhodoLED XL further cements Biofrontera's position as a leader in dermatological treatments, providing healthcare professionals with state-of-the-art tools to enhance patient care.